Genprex, Inc. (GNPX)
3.42
-0.09
(-2.56%)
USD |
NASDAQ |
Sep 03, 16:00
3.48
+0.06
(+1.75%)
After-Hours: 20:00
Genprex Enterprise Value : -13.38M for Sept. 2, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 02, 2026 | -13.38M |
| September 01, 2026 | -13.36M |
| August 31, 2026 | -13.28M |
| August 28, 2026 | -13.30M |
| August 27, 2026 | -13.33M |
| August 26, 2026 | -13.14M |
| August 25, 2026 | -13.13M |
| August 24, 2026 | -13.12M |
| August 21, 2026 | -13.15M |
| August 20, 2026 | -13.15M |
| August 19, 2026 | -13.13M |
| August 18, 2026 | -13.15M |
| August 17, 2026 | -12.89M |
| August 14, 2026 | -12.97M |
| August 13, 2026 | -12.69M |
| August 12, 2026 | -12.76M |
| August 11, 2026 | -12.89M |
| August 10, 2026 | -13.03M |
| August 07, 2026 | -12.99M |
| August 06, 2026 | -12.91M |
| August 05, 2026 | -12.91M |
| August 04, 2026 | -12.92M |
| August 03, 2026 | -12.75M |
| July 31, 2026 | -12.12M |
| July 30, 2026 | -12.09M |
| Date | Value |
|---|---|
| July 29, 2026 | -11.55M |
| July 28, 2026 | -11.09M |
| July 27, 2026 | -11.24M |
| July 24, 2026 | -11.20M |
| July 23, 2026 | -11.36M |
| July 22, 2026 | -10.90M |
| July 21, 2026 | -11.10M |
| July 20, 2026 | -11.50M |
| July 17, 2026 | -11.27M |
| July 16, 2026 | -11.10M |
| July 15, 2026 | -9.687M |
| July 14, 2026 | -9.996M |
| July 13, 2026 | -9.194M |
| July 10, 2026 | -8.919M |
| July 09, 2026 | -8.968M |
| July 08, 2026 | -8.874M |
| July 07, 2026 | -8.573M |
| July 06, 2026 | -8.239M |
| July 02, 2026 | -8.740M |
| July 01, 2026 | -9.204M |
| June 30, 2026 | -9.374M |
| June 29, 2026 | -13.48M |
| June 26, 2026 | -13.57M |
| June 25, 2026 | -13.79M |
| June 24, 2026 | -13.68M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 4.097B |
| Alnylam Pharmaceuticals, Inc. | 35.44B |
| Anika Therapeutics, Inc. | 275.24M |
| Savara, Inc. | 978.85M |
| Vericel Corp. | 2.024B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -4.447M |
| Total Expenses (Quarterly) | 4.447M |
| EPS Diluted (Quarterly) | -9.399 |
| Earnings Yield | -4.64K% |
| Normalized Earnings Yield | -4642.04 |